NEW YORK, April 11 – The University of Geneva has licensed a key DNA-binding technology to Gene Soft, a South San Francisco, Calif.-based biotechnology company that is developing small molecule DNA sequence specific drugs, the organizations said Wednesday.

This technology, developed by Ulrich Laemmi, a professor of molecular biology at the University of Geneva, involves DNA-binding molecules that act to change the structure of chromatin, the complex formed by DNA and the proteins to make chromosomes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

This year's Breakthrough Prize winners include a pair that developed a therapy for spinal muscular atrophy.

The New York Times reports on how white supremacists misconstrue genetic research, concerning many geneticists.

Researchers find that people's genetics influence their success at university, but that it is not the only factor.

In Nature this week: approach to identify genetic variants that affect trait variability, application of read clouds to microbiome samples, and more.